Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1462-1468

  Barkus, Emma ^a,b   Morrison, Paul D ^a   Vuletic, D ^a   Dickson, John C ^c   Ell, Peter J ^c   Pilowsky, Lyn S ^a,c   Brenneisen, Rudolf ^d   Holt, David W ^e   Powell, John ^a   Kapur, Shitij ^a   Murray, Robin M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF BERN   (Switzerland)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cannabis; dopamine; psychosis; SPET; THC

Indexed keywords

DOPAMINE; DRONABINOL; IODOBENZAMIDE I 123; PLACEBO; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS; DOPAMINE RELEASE; EMISSION TOMOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; PUTAMEN; SINGLE PHOTON EMISSION TOMOGRAPHY; SYMPTOM;

ADULT; CORPUS STRIATUM; DOPAMINE; DOUBLE-BLIND METHOD; HALLUCINOGENS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PSYCHOTIC DISORDERS; TETRAHYDROCANNABINOL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 82955215765     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110382465     Document Type: Article

References (41)

1. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, et al. Striatal amphetamine-induced DA release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry. 2004 ; 55: 1001-1006 (Pubitemid 38584612)
2. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987 ; 2: 1483-1486
3. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002 ; 325: 1212-1213 (Pubitemid 35398785)
4. Barkus E, Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med. 2008 ; 38: 1267-1276
5. Barkus EJ, Stirling J, Hopkins RS, Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology. 2006 ; 39: 175-178
6. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009 ; 66: 442-451
7. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology. 2009 ; 34: 759-766
8. Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res. 2001 ; 48: 69-82 (Pubitemid 32241184)
9. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci. 2004 ; 24: 4393-4400 (Pubitemid 38608150)
10. Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M, et al. Brain dopamine response in human opioid addiction. Br J Psychiatry. 2008 ; 193: 65-72 (Pubitemid 351946810)
11. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005 ; 57: 594-608 (Pubitemid 40409699)
12. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2008 ; 198: 587-603
13. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004 ; 29: 1558-1572 (Pubitemid 38982249)
14. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009 ; 259: 413-431
15. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, et al. The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev. 2009 ; 33: 1109-1132
16. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 1997 ; 8: 649-652 (Pubitemid 27128210)
17. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003 ; 83: 1017-1066 (Pubitemid 36828930)
18. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964 ; 86: 1646-1647
19. Goldberg DP, Blackwell B. Psychiatric illness in general practice. A detailed study using a new method of case identification. Br Med J. 1970 ; 1: 439-443
20. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005 ; 20: 349-353 (Pubitemid 40978562)
21. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006 ; 31: 2748-2757 (Pubitemid 44764171)
22. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009 ; 35: 549-562
23. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276 (Pubitemid 18039085)
24. Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci. 2005 ; 25: 10537-10545 (Pubitemid 41628455)
25. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000 ; 20: 423-451 (Pubitemid 30164887)
26. Liem-Moolenaar M, Te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. (2010) Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 00: 1-12 (accessed 7 September 2010).
27. Morrison PD, Murray RM. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull. 2009 ; 35: 668-674
28. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009 ; 39: 1607-1616
29. Naef M, Russmann S, Petersen-Felix S, Brenneisen R. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci. 2004 ; 93: 1176-1184 (Pubitemid 38529691)
30. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry. 1994 ; 164: 16-26
31. Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000 ; 41: 220-227 (Pubitemid 30091339)
32. Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med. 1992 ; 33: 1964-1971
33. Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971 ; 127: 1653-1658
34. Skinner HA. The drug abuse screening test. Addict Behav. 1982 ; 7: 363-371 (Pubitemid 13162181)
35. Soliman A, O'Driscoll GA, Pruessner J, Holahan AL, Boileau I, Gagnon D, et al. Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study. Neuropsychopharmacology. 2008 ; 33: 2033-2041 (Pubitemid 351832609)
36. Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, et al. Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology. 2008 ; 41: 371-378
37. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum?. Neuroimage. 2009 ; 48: 186-190
38. Takahashi H, Fujimura Y, Hayashi M, Takano H, Kato M, Okubo Y, et al. Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol. 2008 ; 11: 413-417 (Pubitemid 351482506)
39. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl). 2003 ; 169: 115-134 (Pubitemid 37129963)
40. Verhoeff NP, Brücke T, Podreka I, Bobeldijk M, Angelberger P, Van Royen EA. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl Med Commun. 1991 ; 12: 687-697
41. Yin HH, Lovinger DM. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci U S A. 2006 ; 103: 8251-8256 (Pubitemid 43801084)